2025 Q3 -tulosraportti
44 päivää sitten42 min
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
175 628
Myynti
Määrä
232 670
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 24 775 | - | - | ||
| 18 823 | - | - | ||
| 10 000 | - | - | ||
| 2 000 | - | - | ||
| 29 978 | - | - |
Ylin
0,219VWAP
Alin
0,213VaihtoMäärä
0,5 2 134 735
VWAP
Ylin
0,219Alin
0,213VaihtoMäärä
0,5 2 134 735
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 2 336 744 | 2 336 744 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 2 336 744 | 2 336 744 | 0 | 0 |
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 24.2. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 26.11.2025 | |
| 2025 Q2 -tulosraportti | 28.8.2025 | |
| 2025 Q1 -tulosraportti | 14.5.2025 | |
| 2024 Q4 -tulosraportti | 25.2.2025 | |
| 2024 Q3 -tulosraportti | 27.11.2024 |
Datan lähde: Quartr, FactSet
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·3 t sittenFollowing Immunovia on Linkedin and it's clear that they are really investing commercially now. They have recruited 3 Account Managers and some other commercial roles. Naturally, this also means increased costs so... hopefully, sales will slowly start to pick up.
·21 t sitten · MuokattuThis probably has more of an indirect effect for Immunovia. Since they adhere to US Medicare regulations. I think Donald Trump might possibly be finished as president. The murder of Renee by that ICE agent (the brownshirt) is the last straw. The question is just how fast it goes downhill. https://m.youtube.com/watch?v=ELtZnnIC6IE A bit more madness when we first scratch the surface of the matter- ·2 päivää sittenAsked AI about the trend of blood tests for cancer diagnostics: (primarily known as Liquid Biopsy or Multi-Cancer Early Detection (MCED)) is currently one of the fastest-growing sectors in medical diagnostics. In terms of market growth and clinical adoption, the field is moving from a "research curiosity" to a "standard of care" at a remarkable pace. 1. Market Growth Rates The industry is currently seeing double-digit annual growth. As of early 2026, market data highlights the following: Compound Annual Growth Rate (CAGR): The liquid biopsy market is expanding at roughly 13% to 18% annually. Market Value: The global liquid biopsy market was valued at approximately $6.17 billion in 2024 and is projected to reach over $22 billion by 2034. Segment Leaders: Genomic and liquid biopsy tests are the fastest-growing sub-segment of all cancer diagnostics, significantly outpacing traditional imaging (like CT scans) and tissue biopsies. 2. Clinical & Adoption Milestones The "growth" isn't just in dollars; it is in how many patients are actually getting these tests: NHS Rollout (UK): In 2025, the NHS in England became the first in the world to roll out liquid biopsy tests for up to 15,000 lung cancer patients and 5,000 breast cancer patients annually. FDA Approvals: A major turning point occurred in mid-2024 when the FDA approved the first blood-based screening test for colorectal cancer (Shield by Guardant Health) for average-risk adults. Public Acceptance: Recent surveys show that over 90% of patients find blood-based cancer testing highly acceptable due to its non-invasive nature compared to traditional "needle" or "surgical" biopsies. 3. Technological Breakthroughs The growth is fueled by the ability to detect cancer years before symptoms appear: Early Detection: Recent studies (such as the PATHFINDER 2 trial) demonstrated that adding a single blood test to standard screenings could find seven times more cancers than standard screenings alone. Time Advantage: Data published in 2025 suggests that tumor-derived mutations can be identified in the bloodstream 3 to 3.5 years before a clinical diagnosis would normally be made. Accuracy: For certain high-risk cancers like pancreatic cancer, new blood tests have reached an accuracy of over 97%. 4. Key Drivers of Growth Medicare/Insurance Coverage: In the U.S., the inclusion of blood-based colorectal tests in the 2025 Medicare fee schedule has drastically increased the volume of tests performed. Shift to Primary Care: Detection is moving out of specialized oncology centers and into "Point-of-Care" (GP offices/retail clinics), which is expected to grow at a rate of 14.7%. AI Integration: AI is now being used to analyze "methylation patterns" in the blood, allowing doctors to not only see if cancer is present but exactly where in the body it is located with over 90% accuracy.
- ·2 päivää sitten · MuokattuGood news in Norway. See below.. (cancer detection) Given that Immunovia gets its blood test right, then today's confidence in the stock is at an all-time low. Blood tests for cancer detection seem to be gaining traction. See: https://www.nrk.no/stor-oslo/ahus-starter-med-stor-undersokelse-for-a-avdekke-prostatakreft-hos-menn-1.17679082·2 päivää sittenWhat trend healthcare is going in is very interesting in itself. And highly relevant for Immunovia. IF ONLY they manage this eventually. Yes, Immunovia has become a bit 50/50, as I see it. Possibly they have a good test, but it will at least take time. Short-term 50/50 for news flow is sparse.
·30.12.2025Have warned about this stock all autumn. Most recently October 7 "do not participate in the new issue". This company only benefits lawyers, investment banks etc etc. Why pay over 900 $ for a cancer test when it only costs 400 $ to get someone "poffad" in Miami, where I have lived.·31.12.2025Why don't you just pop Ivermectin and other such hype snacks then, problem solved, and "you won't get cancer". Stop eating things with sugar. Go to a monastery in Bhutan or something like that.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q3 -tulosraportti
44 päivää sitten42 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·3 t sittenFollowing Immunovia on Linkedin and it's clear that they are really investing commercially now. They have recruited 3 Account Managers and some other commercial roles. Naturally, this also means increased costs so... hopefully, sales will slowly start to pick up.
- ·21 t sitten · MuokattuThis probably has more of an indirect effect for Immunovia. Since they adhere to US Medicare regulations. I think Donald Trump might possibly be finished as president. The murder of Renee by that ICE agent (the brownshirt) is the last straw. The question is just how fast it goes downhill. https://m.youtube.com/watch?v=ELtZnnIC6IE A bit more madness when we first scratch the surface of the matter
- ·2 päivää sittenAsked AI about the trend of blood tests for cancer diagnostics: (primarily known as Liquid Biopsy or Multi-Cancer Early Detection (MCED)) is currently one of the fastest-growing sectors in medical diagnostics. In terms of market growth and clinical adoption, the field is moving from a "research curiosity" to a "standard of care" at a remarkable pace. 1. Market Growth Rates The industry is currently seeing double-digit annual growth. As of early 2026, market data highlights the following: Compound Annual Growth Rate (CAGR): The liquid biopsy market is expanding at roughly 13% to 18% annually. Market Value: The global liquid biopsy market was valued at approximately $6.17 billion in 2024 and is projected to reach over $22 billion by 2034. Segment Leaders: Genomic and liquid biopsy tests are the fastest-growing sub-segment of all cancer diagnostics, significantly outpacing traditional imaging (like CT scans) and tissue biopsies. 2. Clinical & Adoption Milestones The "growth" isn't just in dollars; it is in how many patients are actually getting these tests: NHS Rollout (UK): In 2025, the NHS in England became the first in the world to roll out liquid biopsy tests for up to 15,000 lung cancer patients and 5,000 breast cancer patients annually. FDA Approvals: A major turning point occurred in mid-2024 when the FDA approved the first blood-based screening test for colorectal cancer (Shield by Guardant Health) for average-risk adults. Public Acceptance: Recent surveys show that over 90% of patients find blood-based cancer testing highly acceptable due to its non-invasive nature compared to traditional "needle" or "surgical" biopsies. 3. Technological Breakthroughs The growth is fueled by the ability to detect cancer years before symptoms appear: Early Detection: Recent studies (such as the PATHFINDER 2 trial) demonstrated that adding a single blood test to standard screenings could find seven times more cancers than standard screenings alone. Time Advantage: Data published in 2025 suggests that tumor-derived mutations can be identified in the bloodstream 3 to 3.5 years before a clinical diagnosis would normally be made. Accuracy: For certain high-risk cancers like pancreatic cancer, new blood tests have reached an accuracy of over 97%. 4. Key Drivers of Growth Medicare/Insurance Coverage: In the U.S., the inclusion of blood-based colorectal tests in the 2025 Medicare fee schedule has drastically increased the volume of tests performed. Shift to Primary Care: Detection is moving out of specialized oncology centers and into "Point-of-Care" (GP offices/retail clinics), which is expected to grow at a rate of 14.7%. AI Integration: AI is now being used to analyze "methylation patterns" in the blood, allowing doctors to not only see if cancer is present but exactly where in the body it is located with over 90% accuracy.
- ·2 päivää sitten · MuokattuGood news in Norway. See below.. (cancer detection) Given that Immunovia gets its blood test right, then today's confidence in the stock is at an all-time low. Blood tests for cancer detection seem to be gaining traction. See: https://www.nrk.no/stor-oslo/ahus-starter-med-stor-undersokelse-for-a-avdekke-prostatakreft-hos-menn-1.17679082·2 päivää sittenWhat trend healthcare is going in is very interesting in itself. And highly relevant for Immunovia. IF ONLY they manage this eventually. Yes, Immunovia has become a bit 50/50, as I see it. Possibly they have a good test, but it will at least take time. Short-term 50/50 for news flow is sparse.
- ·30.12.2025Have warned about this stock all autumn. Most recently October 7 "do not participate in the new issue". This company only benefits lawyers, investment banks etc etc. Why pay over 900 $ for a cancer test when it only costs 400 $ to get someone "poffad" in Miami, where I have lived.·31.12.2025Why don't you just pop Ivermectin and other such hype snacks then, problem solved, and "you won't get cancer". Stop eating things with sugar. Go to a monastery in Bhutan or something like that.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
175 628
Myynti
Määrä
232 670
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 24 775 | - | - | ||
| 18 823 | - | - | ||
| 10 000 | - | - | ||
| 2 000 | - | - | ||
| 29 978 | - | - |
Ylin
0,219VWAP
Alin
0,213VaihtoMäärä
0,5 2 134 735
VWAP
Ylin
0,219Alin
0,213VaihtoMäärä
0,5 2 134 735
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 2 336 744 | 2 336 744 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 2 336 744 | 2 336 744 | 0 | 0 |
Asiakkaat katsoivat myös
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 24.2. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 26.11.2025 | |
| 2025 Q2 -tulosraportti | 28.8.2025 | |
| 2025 Q1 -tulosraportti | 14.5.2025 | |
| 2024 Q4 -tulosraportti | 25.2.2025 | |
| 2024 Q3 -tulosraportti | 27.11.2024 |
Datan lähde: Quartr, FactSet
2025 Q3 -tulosraportti
44 päivää sitten42 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 24.2. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 26.11.2025 | |
| 2025 Q2 -tulosraportti | 28.8.2025 | |
| 2025 Q1 -tulosraportti | 14.5.2025 | |
| 2024 Q4 -tulosraportti | 25.2.2025 | |
| 2024 Q3 -tulosraportti | 27.11.2024 |
Datan lähde: Quartr, FactSet
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·3 t sittenFollowing Immunovia on Linkedin and it's clear that they are really investing commercially now. They have recruited 3 Account Managers and some other commercial roles. Naturally, this also means increased costs so... hopefully, sales will slowly start to pick up.
- ·21 t sitten · MuokattuThis probably has more of an indirect effect for Immunovia. Since they adhere to US Medicare regulations. I think Donald Trump might possibly be finished as president. The murder of Renee by that ICE agent (the brownshirt) is the last straw. The question is just how fast it goes downhill. https://m.youtube.com/watch?v=ELtZnnIC6IE A bit more madness when we first scratch the surface of the matter
- ·2 päivää sittenAsked AI about the trend of blood tests for cancer diagnostics: (primarily known as Liquid Biopsy or Multi-Cancer Early Detection (MCED)) is currently one of the fastest-growing sectors in medical diagnostics. In terms of market growth and clinical adoption, the field is moving from a "research curiosity" to a "standard of care" at a remarkable pace. 1. Market Growth Rates The industry is currently seeing double-digit annual growth. As of early 2026, market data highlights the following: Compound Annual Growth Rate (CAGR): The liquid biopsy market is expanding at roughly 13% to 18% annually. Market Value: The global liquid biopsy market was valued at approximately $6.17 billion in 2024 and is projected to reach over $22 billion by 2034. Segment Leaders: Genomic and liquid biopsy tests are the fastest-growing sub-segment of all cancer diagnostics, significantly outpacing traditional imaging (like CT scans) and tissue biopsies. 2. Clinical & Adoption Milestones The "growth" isn't just in dollars; it is in how many patients are actually getting these tests: NHS Rollout (UK): In 2025, the NHS in England became the first in the world to roll out liquid biopsy tests for up to 15,000 lung cancer patients and 5,000 breast cancer patients annually. FDA Approvals: A major turning point occurred in mid-2024 when the FDA approved the first blood-based screening test for colorectal cancer (Shield by Guardant Health) for average-risk adults. Public Acceptance: Recent surveys show that over 90% of patients find blood-based cancer testing highly acceptable due to its non-invasive nature compared to traditional "needle" or "surgical" biopsies. 3. Technological Breakthroughs The growth is fueled by the ability to detect cancer years before symptoms appear: Early Detection: Recent studies (such as the PATHFINDER 2 trial) demonstrated that adding a single blood test to standard screenings could find seven times more cancers than standard screenings alone. Time Advantage: Data published in 2025 suggests that tumor-derived mutations can be identified in the bloodstream 3 to 3.5 years before a clinical diagnosis would normally be made. Accuracy: For certain high-risk cancers like pancreatic cancer, new blood tests have reached an accuracy of over 97%. 4. Key Drivers of Growth Medicare/Insurance Coverage: In the U.S., the inclusion of blood-based colorectal tests in the 2025 Medicare fee schedule has drastically increased the volume of tests performed. Shift to Primary Care: Detection is moving out of specialized oncology centers and into "Point-of-Care" (GP offices/retail clinics), which is expected to grow at a rate of 14.7%. AI Integration: AI is now being used to analyze "methylation patterns" in the blood, allowing doctors to not only see if cancer is present but exactly where in the body it is located with over 90% accuracy.
- ·2 päivää sitten · MuokattuGood news in Norway. See below.. (cancer detection) Given that Immunovia gets its blood test right, then today's confidence in the stock is at an all-time low. Blood tests for cancer detection seem to be gaining traction. See: https://www.nrk.no/stor-oslo/ahus-starter-med-stor-undersokelse-for-a-avdekke-prostatakreft-hos-menn-1.17679082·2 päivää sittenWhat trend healthcare is going in is very interesting in itself. And highly relevant for Immunovia. IF ONLY they manage this eventually. Yes, Immunovia has become a bit 50/50, as I see it. Possibly they have a good test, but it will at least take time. Short-term 50/50 for news flow is sparse.
- ·30.12.2025Have warned about this stock all autumn. Most recently October 7 "do not participate in the new issue". This company only benefits lawyers, investment banks etc etc. Why pay over 900 $ for a cancer test when it only costs 400 $ to get someone "poffad" in Miami, where I have lived.·31.12.2025Why don't you just pop Ivermectin and other such hype snacks then, problem solved, and "you won't get cancer". Stop eating things with sugar. Go to a monastery in Bhutan or something like that.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
175 628
Myynti
Määrä
232 670
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 24 775 | - | - | ||
| 18 823 | - | - | ||
| 10 000 | - | - | ||
| 2 000 | - | - | ||
| 29 978 | - | - |
Ylin
0,219VWAP
Alin
0,213VaihtoMäärä
0,5 2 134 735
VWAP
Ylin
0,219Alin
0,213VaihtoMäärä
0,5 2 134 735
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 2 336 744 | 2 336 744 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 2 336 744 | 2 336 744 | 0 | 0 |